Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6–18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial

The Lancet Microbe · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles